Nasus Pharma Advances NS002 Toward Pivotal Anaphylaxis Study
TEL AVIV, Israel — September 14, 2026 Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TEL AVIV, Israel — September 14, 2026 Nasus Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA)...
San Diego, U.S. | April 15, 2026 ARS Pharmaceuticals has achieved a major regulatory milestone with Health Canada approval...
